Thr453
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr453  -  TTK (human)

Site Information
DPkSICktPsSNtLD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 471487

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 15 ) , mutation of modification site ( 1 , 13 ) , phospho-antibody ( 13 ) , western blotting ( 1 , 13 )
Disease tissue studied:
bone cancer ( 13 ) , breast cancer ( 1 ) , cervical cancer ( 13 ) , cervical adenocarcinoma ( 13 ) , gastric cancer ( 10 , 11 ) , gastric carcinoma ( 10 , 11 ) , leukemia ( 6 ) , chronic lymphocytic leukemia ( 6 ) , prostate cancer ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Kinases, in vitro:
CDK2 (human) ( 13 )
Treatments:
seliciclib ( 13 )

Downstream Regulation
Effects of modification on TTK:
molecular association, regulation ( 1 ) , protein stabilization ( 1 )
Induce interaction with:
CDKN3 (human) ( 1 )

References 

1

Srinivas V, et al. (2015) The Tumor Suppressor Cdkn3 Is Required for Maintaining the Proper Number of Centrosomes by Regulating the Centrosomal Stability of Mps1. Cell Rep 13, 1569-77
26586430   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

4

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

5

Rikova K (2010) CST Curation Set: 10037; Year: 2010; Biosample/Treatment: cell line, DFCI ERC11 serum free/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

6

Rikova K (2010) CST Curation Set: 10035; Year: 2010; Biosample/Treatment: cell line, DFCI ERC11/untreated; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

7

Rikova K (2010) CST Curation Set: 10039; Year: 2010; Biosample/Treatment: cell line, DFCI ERC11 triple/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

8

Possemato A (2010) CST Curation Set: 9354; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Pp[ST]
Curated Info

9

Possemato A (2010) CST Curation Set: 9353; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Pp[ST]
Curated Info

10

Rikova K (2010) CST Curation Set: 9329; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

11

Rikova K (2010) CST Curation Set: 9328; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

12

Kang J, Chen Y, Zhao Y, Yu H (2007) Autophosphorylation-dependent activation of human Mps1 is required for the spindle checkpoint. Proc Natl Acad Sci U S A 104, 20232-7
18083840   Curated Info

13

Kasbek C, et al. (2007) Preventing the degradation of mps1 at centrosomes is sufficient to cause centrosome reduplication in human cells. Mol Biol Cell 18, 4457-69
17804818   Curated Info

14

Possemato A (2006) CST Curation Set: 1662; Year: 2006; Biosample/Treatment: cell line, NCI-H1703/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

15

Possemato A (2006) CST Curation Set: 1663; Year: 2006; Biosample/Treatment: cell line, NCI-H1703/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info